Corbus Pharmaceuticals Holdings, Inc. (CRBP) vs Spero Therapeutics, Inc. (SPRO)

Corbus Pharmaceuticals Holdings, Inc. and Spero Therapeutics, Inc. are both Biotechnology companies. Corbus Pharmaceuticals Holdings, Inc. and Spero Therapeutics, Inc. are of similar size ($68.1M and $62.3M). Corbus Pharmaceuticals Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Spero Therapeutics, Inc. trades at 7.7×. Spero Therapeutics, Inc. grew revenue faster over the last twelve months: 37.2% against −73.7%. Across the 14 metrics below, Spero Therapeutics, Inc. leads on 11 and Corbus Pharmaceuticals Holdings, Inc. on 3.

Valuation

Metric CRBP SPRO Biotechnology median
P/E n/m 7.71 10.85
P/S 45.62 1.02 9.49
P/B 0.69 1.42 2.18
Price to free cash flow n/m 3.20 25.85
EV/EBITDA 0.24 1.96 0.70
EV/Sales (16.59) 0.19 8.99
Earnings yield (170.99%) 12.96% (31.76%)
Free cash flow yield (123.39%) 31.21% (21.84%)

Profitability

Metric CRBP SPRO Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (95.58%) 19.17% (50.82%)
Return on assets (80.85%) 12.85% (46.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CRBP SPRO Biotechnology median
Revenue growth (TTM) (73.69%) 37.24% 6.96%
EPS growth (last fiscal year) (60.33%) 111.81% 29.88%
Revenue growth, 5-year CAGR (14.34%) 48.25% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRBP SPRO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.71 6.12 4.84
Net debt to EBITDA 1.90 (6.38) 1.01

Dividend

Metric CRBP SPRO Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric CRBP SPRO Biotechnology median
Market cap 68.08m 62.31m 163.56m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack